SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kotani, T
Right arrow Articles by Hanafusa, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kotani, T
Right arrow Articles by Hanafusa, T
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus

T Kotani

First Department of Internal Medicine, Osaka Medical College, Daigaku-Machi 2-7, Takatsuki, Osaka 569-8686, Japan, in1242{at}poh.osaka-med.ac.jp

T Takeuchi

Y Kawasaki

S Hirano

Y Tabushi

M Kagitani

S Makino

T Hanafusa

First Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka, Japan

Cold agglutinin disease (CAD) is a rare cause of anaemia in patients with systemic lupus erythematosus (SLE). CAD is usually refractory to glucocorticosteroid, and other immunosuppressive and/or cytotoxic therapies. We report the case of a 55-years old woman with SLE and CAD that did not respond to high-dose methylprednisolone, cyclosporin A, and double filtration plasma pheresis. Because several recent case reports and studies have indicated promising results of rituximab treatment for CAD and for SLE, rituximab was given weekly at 375 mg/m2 in two doses. The rituximab was well tolerated, and there were no adverse effects. The hemolysis and SLE improved markedly, and the patient remained disease free eight months later. This is the first report of successful rituximab treatment of CAD in a patient with SLE. We conclude that rituximab is worth trying in such patients if they fail to respond to conventional treatment.

Key Words: cold agglutinin disease • hemolytic anaemia • rituximab • systemic lupus erythematosus

Lupus, Vol. 15, No. 10, 683-685 (2006)
DOI: 10.1177/0961203306070983
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
M Ramos-Casals, M. Soto, M. Cuadrado, and M. Khamashta
Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases
Lupus, August 1, 2009; 18(9): 767 - 776.
[Abstract] [PDF]

Home page
 LupusHome page
R Abdwani and R Mani
Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE
Lupus, April 1, 2009; 18(5): 460 - 464.
[Abstract] [PDF]

Home page
 Ann Rheum DisHome page
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22.
[Full Text] [PDF]


Advertisement